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Glycosylation site occupancy in 
health, congenital disorder of 
glycosylation and fatty liver disease
Andreas J. Hülsmeier1, Micha Tobler2, Patricie Burda2 & Thierry Hennet1
Glycosylation is an integral part in health and disease, as emphasized by the growing number of 
identified glycosylation defects. In humans, proteins are modified with a diverse range of glycoforms 
synthesized in complex biosynthetic pathways. Glycosylation disorders have been described in 
congenital disorders of glycosylation (CDG) as well as in acquired disease conditions such and non-
alcoholic fatty liver disease (NAFLD). A hallmark in a subset of CDG cases is the reduced glycosylation 
site occupancy of asparagine-linked glycans. Using an optimized method protocol, we determined 
the glycosylation site occupancy from four proteins of hepatic and lymphatic origin from CDG and 
NAFLD patients. We found variable degrees of site occupancy, depending on the tissue of origin and 
the disease condition. In CDG glycosylation sites of IgG2 and IgA1 were occupied to normal levels. In 
NAFLD haptoglobin and transferrin glycosylation sites were hyper-glycosylated, a property qualifying 
for its use as a potential biomarker. Furthermore, we observed, that glycosylation sites of liver-
originating transferrin and haptoglobin are differentially occupied under physiological conditions, a 
further instance not noticed in serum proteins to date. Our findings suggest the use of serum protein 
hyperglycosylation as a biomarker for early stages of NAFLD.
Alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD) and congenital disorders of glycosyl-
ation (CDG) share common symptoms manifested by the development of fatty liver, liver fibrosis/cirrhosis and 
insulin resistance1. Whereas CDG constitutes a group of autosomal recessive inherited diseases, ALD and NAFLD 
are considered as acquired disease conditions2,3. Although, a recent study of twins based on MRI assessments 
suggests that hepatic steatosis and fibrosis are heritable traits4. NAFLD can be grouped into benign liver steatosis 
and the more progressed and inflammatory form of non-alcoholic steatohepatitis (NASH). NAFLD/NASH is also 
been described as the manifestation of the metabolic syndrome in the liver1. A recent report describes NASH as a 
preceding determinant for the development of the metabolic syndrome with potential implications on the clinical 
diagnosis and treatment5. The search of biomarkers for non-invasive diagnosis, addressing the prevalence and the 
scope of clinical presentations is a major focus in NAFLD research6. ALD and NASH share common traits, such 
as the occurrence of Mallory-Denk bodies in the cytoplasm of liver cells, upregulation of the cytochrome P2E1 
with subsequent increase in reactive oxygen species and accumulation of 4-hydroxy-2-nonenal in the liver tissue. 
The accumulation of 4-hydroxy-2-nonenal is made responsible for the development of hepatocellular carcinoma 
in late stage disease conditions. For the differentiation of ALD and NASH non-invasive diagnostic measures are 
lacking and liver biopsies are required for diagnosis7. Serum values of aminotransferases and gamma-glutamyl 
transpeptidase and the mean corpuscular volume of erythrocytes are overlapping between NASH and ALD sam-
ples. Nevertheless, a direct comparison of levels of carbohydrate deficient transferrin (CDT) in serum can be 
used to differentiate between NASH and alcoholic hepatitis patients8. N-linked glycosylation profiles have been 
used for diagnosing liver cirrhosis and to differentiate patients with hepatocellular carcinoma from cirrhotic 
patients9,10. Accordingly, an increase of a-galactosylated N-glycans with concomitant decrease of the galacto-
sylated glycoforms serum samples, and in the Fc-region of serum IgG has been proposed as a biomarker for 
diagnosing advanced NASH related fibrosis and differentiating between liver steatosis and NASH11,12.
CDG is a multi-systemic condition affecting various glycosylation pathways. A new nomenclature addressing 
CDG forms deriving from differing glycan biosynthetic pathways was proposed, using the official gene symbol 
of the protein involved followed by “-CDG”13. A subset of CDG forms derived from the N-glycan biosynthesis 
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typically display reduced glycosylation site occupancy of secreted proteins. The reduced glycosylation frequency 
is due to gene defects of enzymes mediating the assembly of the precursor dolichol-linked oligosaccharide or 
the oligosaccharide transfer to the newly synthesized glycoprotein. Other forms of CDG display aberrant glycan 
structures, but normal glycosylation frequency on secreted proteins, due to gene defects in proteins involved 
in the glycan maturation and processing in the Golgi. A common symptom to CDG and ALD is a reduced 
N-glycosylation site occupancy, and is characterized by an increase of CDT in the blood of affected patients14. 
CDT levels are routinely assessed by isoelectric focusing gel electrophoresis, HPLC analysis or liquid chromatog-
raphy coupled mass spectrometry (LC-MS)15–17. We have previously developed a multiple reaction monitoring 
mass spectrometric (MRM-MS) assay to directly determine the N-glycosylation site occupancy at the peptide 
level, and found decreasing site occupancy in correlation with the severity of the clinical symptoms in the respec-
tive CDG forms18. Here we devised an optimized protocol, omitting immunoaffinity purification and simplified 
sample preparation procedures for the semi-quantitative determination of the N-glycosylation site occupancy 
of four serum proteins of hepatic and lymphatic tissue origin. We validated this protocol using a serum cohort 
from CDG patients with known hypoglycosylation phenotypes and explored its use for determining potential 
biomarkers for NAFLD. We selected the serum glycoproteins transferrin, haptoglobin, IgG2 and IgA1 to compare 
the glycosylation status of proteins derived from hepatic and lymphatic origin.
Serum IgG glycosylation has been explored in search for biomarkers for autoimmune and congenital disease 
conditions. Changes in the N-glycan structures at the glycosylation site in the conserved Fc-region of the IgG 
heavy chain have been shown to modulate the binding of IgG to Fc-gamma receptors and C-type lectins, thereby 
influencing the inflammatory responses in autoimmune conditions (reviewed in refs 19 and 20). In congenital 
defects, abnormal IgG N-glycosylation for classical galactosaemia and MAN1B1-CDG-specific IgG glycans were 
described recently21,22. The variable Fab-region of IgG and IgA can also contain glycosylated sequons and might 
have emerged via somatic hypermutation19,23. The significance of Fab-glycosylation of IgG in (patho-)physiology 
and immunity has been discussed recently24. IgA1 contains two N-glycosylation sites in the constant Fc region 
and up to six occupied O-glycosylation sites in the hinge region. GlcNAc terminating IgA1 glycans selectively 
bind to the transferrin receptor, mediating effector functions in IgA nephropathy. Whereas glycans terminat-
ing with galactose serve as ligands for the asialoglycoprotein receptor, mediating the clearance of IgA from the 
serum23. Aberrant glycosylation of IgA1 has been ascribed to result in the depositions in the glomeruli of the 
kidney mesangium in IgA nephropathy25.
Transferrin and haptoglobin are serum glycoproteins produced in hepatocytes. Haptoglobin contains four 
N-glycosylation sites and belongs to the acute phase proteins, whose blood levels and glycosylation profiles 
change during inflammatory reactions in sepsis, tissue damage or cancer26. Haptoglobin binds free hemoglobin 
for degradation in the liver and for iron recycling. The binding characteristic of haptoglobin to surface receptors 
of macrophages in the tumor microenvironment might play a crucial role for tumor cell growth and survival27. 
The iron-binding blood protein transferrin contains two N-linked glycosylation sites. Transferrin has been uti-
lized since decades as a biomarker for monitoring alcohol abuse28. Carbohydrate deficient transferrin is charac-
terized by a reduced N-glycosylation site occupancy or alterations in N-glycosylation profiles and is used as a 
versatile diagnostic marker in CDG research. Serum transferrin glycoforms are monitored by isoelectric focusing 
gel electrophoresis, HPLC or mass spectrometric approaches16,18,28,29.
Results
Reduced site occupancy of N-linked glycosylation sites is a hallmark in CDG and ALD. Previously, we devel-
oped a MRM-MS based method for directly determining the site occupancy at the peptide level and found 
decreasing occupancy in correlation with the severity of the clinical symptoms displayed in CDG with reduced 
N-glycosylation frequency18. Here we devised a sample preparation protocol in favor of simplicity, omitting pre-
vious glycoprotein enrichment by affinity purification. One μ l of serum was reduced and alkylated before trypsin 
digestion, and a single sample transfer was required for isolating the tryptic peptides using a cation exchange 
resin. N-linked glycopeptides were enzymatically de-glycosylated with PNGase F in 18O-water containing buffer, 
introducing the 18O-isotope to the newly formed aspartic acid residue after deglycosylation. Isotopic labeling 
of the glycosylation sites helps to differentiate PNGase F reaction products from spontaneous deamination 
reactions of unoccupied asparagine residues. C-terminally isotope labeled standard peptides corresponding 
to unglycosylated and deglycosylated glycopeptide sequences were added to the samples to assess the relative 
N-glycosylation site occupancy. One glycosylation site per glycoprotein was assayed, based on robust detection in 
LC-MS-MS peptide sequencing, using the Mascot peptide score algorithm (Table 1).
Testing the linearity in the peptide detection. The linearity in the peptide detection was tested by load-
ing increasing amounts of sample onto the nanobore column. We obtained a linear relationship of the amount of 
sample relative to the standard peptides when loading 1 to 6 percent of the sample preparation with r2 values of 
0.98 and 0.99 after regression analyses (Fig. 1). Accordingly, we assayed for linearity with increasing amounts of 
standard peptides added to four percent of sample. We obtained a linear relationship with the standard peptides 
at concentrations from 25 to 150 fmol/μ l for the transferrin, IgA1 and IgG2 peptides. The corresponding r2 values 
were calculated between 0.94 and 1.00 after regression analyses. For the haptoglobin peptides a 10-fold lower 
concentration was used in the standard peptide mixture, due to higher signal intensities observed for this peptide 
(Fig. 2). For the linearity tests technical triplicates were necessary to obtain a precise linear fit. Therefore, three 
replicates starting with the trypsin digests were prepared for each serum sample analyzed.
Occurrence of spontaneous deamination. The occurrence of spontaneous deamination of asparagine 
was detected by the presence of 16O-aspartic acids in the glycosylation sequon. We observed a varying degree 
of deamination reactions, depending on the peptide sequence ranging from 2.9% in the haptoglobin peptide 
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to 12.9% in IgA1 throughout all samples analyzed (Supplemental Table 2). Since the deglycosylation reaction 
was performed in 18O-containing buffer, 16O-aspartic acid within the sequon must have formed prior PNGase 
F mediated deglycosylation. Therefore, these values add towards the unglycosylated peptide count. For the IgG 
peptide only 18O-asparic acid could be detected, indicating that the amount of 16O-water in the reaction buffer is 
low and evades detection with the instrumentation used in this study (Table 2). Therefore, it appears likely that 
the content of 16O-water in the buffer used for the deglycosylation reaction did not contribute significantly to the 
16O-aspartic acid counts.
Serum samples. Cohorts of 10 CDG and 12 NAFLD with varying severities of clinical symptoms were 
selected to assay the N-glycosylation site occupancies. The CDG samples were collected from patients with 
mild, moderate and severe symptoms according to the scoring system proposed by Grünewald et al.30. The CDG 
samples selected comprised defects in the biosynthesis upstream to the transfer of the preassembled oligosac-
charide precursor to the newly synthesized protein (i.e. PMM2-CDG, ALG11-CDG, ALG1-CDG, ALG6-CDG, 
MPDU1-CDG, RFT1-CDG, see Table 2). These CDGs are characterized by a reduced N-glycosylation site 
occupancy in serum proteins such as the diagnostic marker protein transferrin. The liver disease samples 
were obtained from patients with NAFLD activity scores ranging from less than 3 to 6 (Table 2)31. Reduced 
N-glycosylation site occupancies were observed for the CDG samples with liver synthesized transferrin and hap-
toglobin, whereas no change in glycosylation frequency was observed with the glycopeptides from the immuno-
globulins IgA1 and IgG2. It stands out, that under physiological conditions N-glycosylation sites are differentially 
glycosylated, depending on the glycoprotein. This is evident when comparing the transferrin and haptoglobin gly-
copeptides (Fig. 3). Both proteins are mainly synthesized in hepatocytes. Typically, transferrin contains two and 
haptoglobin contains four N-linked glycosylation sites. A third N-linked glycosylation site has been described at 
a non-canonical NXC sequon within the human transferrin at Asn491. This glycosylation site has been described 
Protein Peptide m/z Charge Fragments
av. RT 
(min)
av. 
dot p Description
sp|P02787|TRFE_HUMAN K.ILRQQQHLFGSNVTDCSGNFCLFR.S 727.6059 4 y4 b132+ b142+ b152+ 36.7 0.81 standard-N
K.ILRQQQHLFGSNVTDCSGNFCLFR.S 727.8519 4 y4 b132+ b142+ b152+ 37.1 0.80 standard-D
K.ILRQQQHLFGSNVTDCSGNFCLFR.S 725.3498 4 y4 b132+ b142+ b152+ 37.1 0.76 deamination-16O
K.ILRQQQHLFGSNVTDCSGNFCLFR.S 725.8509 4 y4 b132+ b142+ b152+ 37.1 0.81 deamination-18O
K.ILRQQQHLFGSNVTDCSGNFCLFR.S 725.1038 4 y4 b132+ b142+ b152+ 36.7 0.80 no deamination
sp|P00738|HPT_HUMAN K.VVLHPNYSQVDIGLIK.L 601.6800 3 y6 y142+ b9 b102+ 36.1 0.73 standard-N
K.VVLHPNYSQVDIGLIK.L 602.0080 3 y6 y142+ b9 b102+ 36.5 0.72 standard-D
K.VVLHPNYSQVDIGLIK.L 599.3366 3 y6 y142+ b9 b102+ 36.5 0.67 deamination-16O
K.VVLHPNYSQVDIGLIK.L 600.0047 3 y6 y142+ b9 b102+ 36.5 0.88 deamination-18O
K.VVLHPNYSQVDIGLIK.L 599.0086 3 y6 y142+ b9 b102+ 36.1 0.73 no deamination
sp|P01876|IGHA1_HUMAN R.LSLHRPALEDLLLGSEANLTCTLTGLR.D 744.1571 4 y10 y11 b11 b122+ 43.4 0.74 standard-N
R.LSLHRPALEDLLLGSEANLTCTLTGLR.D 744.4031 4 y10 y11 b11 b122+ 44.2 0.76 standard-D
R.LSLHRPALEDLLLGSEANLTCTLTGLR.D 741.9010 4 y10 y11 b11 b122+ 44.2 0.63 deamination-16O
R.LSLHRPALEDLLLGSEANLTCTLTGLR.D 742.4021 4 y10 y11 b11 b122+ 44.2 0.71 deamination-18O
R.LSLHRPALEDLLLGSEANLTCTLTGLR.D 741.6550 4 y10 y11 b11 b122+ 43.4 0.70 no deamination
sp|P01859|IGHG2_HUMAN K.TKPREEQFNSTFR.V 825.4171 2 y4 y7 y112+ b9 28.0 0.75 standard-N
K.TKPREEQFNSTFR.V 825.9091 2 y4 y7 y112+ b9 28.6 0.81 standard-D
K.TKPREEQFNSTFR.V 820.9050 2 y4 y7 y112+ b9 28.6 na deamination-16O
K.TKPREEQFNSTFR.V 821.9071 2 y4 y7 y112+ b9 28.6 0.86 deamination-18O
K.TKPREEQFNSTFR.V 820.4130 2 y4 y7 y112+ b9 28.0 na no deamination
Table 1.  Peptides used to determine the N-glycosylation site occupancies. The areas of the MRM 
transitions corresponding to the fragment ions b132+, b142+, b152+ of the transferrin peptide, the y142+, b9, b102+ 
of haptoglobin peptide, the y7, b182+ of the IgA1 peptide and the y112+, y7, b9 of the IgG2 peptide were used for 
semi-quantitative computation of the N-glycosylation site occupancies. The deaminated asparagine residues of 
the N-glycosylation sequons are marked with N. The stable isotope labeled lysine and arginine residues of the 
standard peptides are labeled with K and R, respectively. C denotes carbamidomethylated cysteine residues. The 
synthetic peptides denoted with standard-N or standard-D were added to the sampled prior MRM-MS analyses. 
The Swiss-Prot designations for the proteins are shown. The dotp values are the similarity measures between 
product peak areas and the corresponding intensities in the spectral library used in Skyline. The average dotp 
values were calculated from manually validated MRM transitions of the peptides. The dotp values for all 
peptides investigated are listed in Supplemental data dotp values.xlsx. “na” = not applicable, for those peptides 
no product peak areas could be validated.
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to be occupied at 2 mol% in a commercially available human transferrin preparation and is not always detectable 
in serum protein preparations32,33. Whereas the transferrin peptide is almost completely glycosylated in healthy 
individuals, only 56% of the haptoglobin peptide at Asn241 is glycosylated on average. Likewise, the IgG2 peptide 
is completely glycosylated and the IgA1 glycopeptide is glycosylated to 85% in healthy control sera. The glyco-
sylation sites tested to date were occupied to nearly 100% in healthy control serum samples18. The observation 
of differential degrees of glycosylation, depending on the glycoprotein is unprecedented and appears to be a 
tissue-independent cellular phenomenon.
CDG and NAFLD. In CDG the extent of hypoglycosylation of haptoglobin can reach to as low as 3% site 
occupancy as seen in CDG samples with a severe clinical display (PMM2-CDG, Alg6-CDG, RFT1-CDG, Table 2), 
whereas for the transferrin glycosylation site the lowest value measured was 72% (RFT1-CDG, Table 2), high-
lighting the dynamic range of N-glycosylation site occupancies for serum glycoproteins. Reduced site occupancy 
for the IgA1 and IgG2 glycopeptides could not be observed in any of the CDG or NAFLD samples analyzed in this 
study (Fig. 3C,D). On the other hand, for the transferrin and haptoglobin glycopeptides of the NAFLD samples an 
increased glycosylation frequency was detected. The increase observed with the transferrin peptide corresponds 
to a mean value of 94 raised to 96% site occupancy (NASH group, Fig. 3A). Although the difference is minimal, 
a p-value of 0.026 was calculated after statistical evaluation, using the Mann-Whitney-test. An increased glyco-
sylation within the steatosis samples was pronounced when analyzing the haptoglobin glycopeptide (Fig. 3B). 
The average site occupancy rose from 56 to 68%, compared to the healthy control samples. Hyperglycosylation 
appears to occur early during the development of liver steatosis in NAFLD. An increase in site occupancy was 
observed in the steatosis samples, whereas the site occupancy of the haptoglobin peptide in the NASH samples 
Figure 1. Linear relationship in the ratio of standard peptides with increasing amounts of sample. 
Increasing amounts of the sample preparation were dissolved with the standard peptide mix and subjected 
to LC-MRM-MS. The areas of the sample per area of the standard peptides are plotted against the amounts 
of sample. Data points are displayed as mean values from triplicate sample preparations, and the error 
bars indicate the standard error of mean (SEM) values. Linear regression analyses was performed for the 
deglycosylated transferrin (a), r2 = 0.99), haptoglobin (b), r2 = 0.98), IgA1 (c), r2 = 0.99) and IgG2 peptides (d), 
r2 = 0.99).
www.nature.com/scientificreports/
5Scientific RepoRts | 6:33927 | DOI: 10.1038/srep33927
is heterogeneous, varying from mildly hypo- to hyperglycosylation. On the other hand, statistical comparison 
among the diseased groups did not yield significance in the difference neither between severe versus moderate or 
moderate versus mild CDG nor between the steatosis and NASH group (Supplemental Table 3).The variability 
in the NASH samples reflects the heterogeneity within this NAFLD classification. Notably, for the sample with 
the lowest site occupancy in the NASH group, a differential diagnosis was indicated for viral hepatitis (ID 022, 
Table 3). This patient with an NAS score of 6 also displayed the most advanced fibrosis stage. In contrast, patient 
019 has a similar NAS score, but displayed only a mild fibrosis stage. It remains to be shown to what extent a 
reduced N-glycosylation site occupancy correlates with the formation of liver fibrosis. The hyperglycosylation 
phenotype of haptoglobin in NAFLD sera was not visible in Western blot analyses (Fig. 4, Supplemental Fig. 2). 
Possibly, the increase in mass due to additional N-glycosylation is not resolved during SDS-PAGE. The gain in 
mass of hyperglycosylated haptoglobin may be insufficient to result in a significant shift in the protein migration 
that can be resolved within in the mass range of haptoglobin. On the other hand, hypoglycosylation of haptoglo-
bin is clearly resolved in CDG samples. In agreement with earlier findings, the degree of underglycosylation of 
haptoglobin correlates with the severity of the clinical CDG manifestations18 Likewise, with isoelectric focusing 
gel electrophoreses the CDG samples were clearly recognized, whereas the NAFLD samples were without patho-
logical findings (Supplemental Fig. 1).
Discussion
In this pilot study, we analyzed the N-glycosylation sites from liver derived glycoproteins and glycoproteins of 
lymphatic origin, using sample cohorts from CDG and NAFLD patients together with healthy control sera. Using 
an optimized sample preparation protocol, four glycoproteins, haptoglobin, transferrin, IgG2 and IgA1 were 
Figure 2. Linear relationship of the ratio of sample derived peptides with increasing amounts of standard 
peptides. Increasing concentrations of the standard peptide mix were added to the sample before subjecting to 
LC-MRM-MS (> 70% purity, Supplemental Fig. 3). The areas of the sample per area of the standard peptides are 
plotted against the standard peptide concentrations. Data points are displayed as mean values from triplicate 
sample preparations, and the error bars indicate the standard error of mean values. Linear regression analyses 
was performed for the deglycosylated transferrin ((a), r2 = 1.00), haptoglobin ((b), r2 = 0.99), IgA1 ((c), r2 = 0.94) 
and IgG2 peptides ((d), r2 = 0.98).
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analyzed. Our results show that in comparison to healthy controls, haptoglobin is hyperglycosylated in liver ste-
atosis patients, suggesting hyperglycosylation as a diagnostic marker for early stage NAFLD. Furthermore, we 
show that IgG2 and IgA1 of CDG patients are normally glycosylated. We found that serum glycoproteins are 
glycosylated to varying degrees under physiological conditions, an instance not noticed in serum proteins to date.
Increased levels of CDT are a common hallmark in ALD and CDG, and the absence of entire glycan chains 
in CDT has been shown18,29. Here we provide direct evidence that IgA1 and IgG2 glycosylation levels are not 
affected in CDG patients with a hypoglycosylation phenotype of serum transferrin and haptoglobin. Whereas 
for the IgG2 peptide no unglycosylated sequon could be detected, the glycosylation level of IgA1was determined 
to average at 82 to 90% site occupancy. The normal glycosylation levels of the immunoglobulins in CDG point 
to compensatory or alternative biosynthetic processes in lymphatic tissues yielding homeostatic N-glycosylation 
levels. Another explanation for this observation may be a rapid clearance of unglycosylated immunoglobulins 
in the blood via an as yet unknown processes analogous to the asialoglycoprotein receptor mediated clearance 
of IgA from the serum23. Glycosylation of the Fc-region is important for mediating the effector functions via 
binding to the Fc-receptors to regulate immune responses20. De-sialylated, galactose exposing glycoproteins are 
recognized by the hepatic asialoglycoprotein receptor and rapidly cleared from the blood circulation34. The pres-
ence of high mannose N-glycan accelerates the clearance rate of IgG through binding to the mannose receptor 
present on immune cells in mice35. Complete absence of Fc region glycosylation however results in the loss of 
effector functions in vivo as well as decreased stability and increased protein aggregation in vitro, which might 
explain the observed absence of unglycosylated IgG in the serum samples analyzed in this study20,36. Our obser-
vations that the liver derived transferrin and haptoglobin glycopeptides are hypoglycosylated, and the immuno-
globulins are not affected in the CDG cases analyzed, are in good agreement with findings described by Dupre 
et al.37. In Western blot analyses of IgG from serum and peripheral blood mononuclear cell homogenates as well 
as of the glucose transporter GLUT-1 in skin fibroblast homogenate, no indications for underglycosylation in 
ID Sample
OMIM 
entry
Clinical  
score
TRFE HPT IGHA1 IGHG2
mean SEM mean SEM mean SEM mean SEM
001 PMM2-CDG 601785 * 86 2.8 3 1.0 82 2.8 100 0.0
002 PMM2-CDG 601785 mild 90 2.1 32 4.6 83 1.0 100 0.0
003 PMM2-CDG 601785 mild/moderate 91 0.7 24 3.1 86 1.0 100 0.0
004 PMM2-CDG 601785 moderate 91 1.0 13 2.2 87 0.2 100 0.0
005 PMM2-CDG 601785 severe 84 1.8 3 0.5 86 2.1 100 0.0
034 AlG11-CDG 613661 * 94 0.1 28 1.2 90 2.7 100 0.0
036 AlLG1-CDG 608540 moderate 82 2.1 7 0.4 91 0.1 100 0.0
037 ALG6-CDG 603147 severe 85 0.5 3 0.3 90 0.5 100 0.0
038 MPDU1-CDG 604041 moderate/severe 91 0.5 12 3.4 87 1.7 100 0.0
039 RFT1-CDG 612015 severe 72 1.7 3 0.7 91 1.8 100 0.0
007 healthy na na 93 0.9 61 2.5 84 1.8 100 0.0
008 healthy na na 94 0.5 57 3.2 86 1.6 100 0.0
009 healthy na na 93 1.1 54 1.8 85 1.3 100 0.0
010 healthy na na 95 0.5 52 3.1 84 1.3 100 0.0
011 healthy na na 95 0.5 56 6.5 86 4.3 100 0.0
012 Steatosis nd < 3 95 1.4 73 4.0 86 1.9 100 0.0
013 Steatosis nd < 3 94 0.5 71 5.6 85 1.0 100 0.0
015 Steatosis nd < 3 95 0.7 61 5.8 84 4.0 100 0.0
016 Steatosis nd < 3 95 0.5 68 1.9 87 1.4 100 0.0
014 NASH nd 5 95 0.2 69 1.9 86 1.5 100 0.0
017 NASH nd 3 95 0.8 59 5.2 86 0.9 100 0.0
018 NASH nd 4 96 1.0 64 1.4 86 1.9 100 0.0
019 NASH nd 5–6 95 0.7 69 4.1 82 1.4 100 0.0
020 NASH nd 4 95 1.5 60 12.3 88 2.6 100 0.0
021 NASH nd 4 94 0.7 53 4.4 88 3.3 100 0.0
022 NASH nd 6 95 1.3 43 3.9 91 1.5 100 0.0
023 NASH nd * 94 0.7 58 11.5 90 2.0 100 0.0
Table 2.  N-glycosylation site occupancies in health and liver disease conditions. The values for each 
glycosylation site are averaged from three technical replicates, starting with the serum sample preparation. 
SEM = standard error of mean. Average values derived from 5 samples from healthy serum, 4 liver steatosis 
samples and 8 NASH samples. OMIM = Online Mendelian Inheritance in Man, na = not applicable, nd = not 
determined, ID = unique sample identifier, TRFE = transferrin, HPT = haptoglobin, IGHA1 = human IgA1, 
IGHG2 = human IgG2, (*) = no clinical information available. The clinical score values are displayed according 
to Grünewald et al. or Kleiner et al. (NAFLD activity scores), respectively30,31.
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PMM2-CDG samples were detected. Based on their findings with further glycoproteins in different cell types, the 
authors concluded that hypoglycosylation of proteins is tissue dependent in PMM2-CDG.
Previously, we found a preferential glycosylation of the first N-linked glycosylation sites and a higher suscep-
tibility of the second site to hypoglycosylation in transferrin and α 1-antitrypsin. Hypoglycosylation was found to 
correlate with the severity of the clinical symptoms in CDG. Furthermore, the level of hypoglycosylation detected 
in transferrin of the patient samples reached as low as 41% for the most severe CDG cases18. Here we selected 
one glycosylation site per protein based on the detectability in LC-MS after proteolytic digestion with a single 
protease. The serum samples were prepared with minimal sample manipulations, omitting immunoaffinity puri-
fication of the proteins. CDG samples with various gene defects were selected to validate the sample preparation 
protocol. In this study, the lowest detected glycosylation site occupancy of the corresponding transferrin pep-
tides was found to be 72% for equally severe diseased patients. The greater range in hypoglycosylation observed 
with the previous method is of advantage for assessing the severity of the clinical phenotype using transferrin as 
the diagnostic marker, and can be explained by an enrichment-bias towards unglycosylated transferrin epitopes 
induced by the immunoaffinity purification18. Therefore, the values obtained in this study most likely present a 
more precise description of the samples analyzed, since a bias in the sample preparation due to immunoaffin-
ity enrichment was precluded. We found a dramatic dynamic range of hypoglycosylation with the haptoglo-
bin peptide. In the healthy control samples the haptoglobin peptide is glycosylated to 56% only, a value so far 
not observed in proteins in non-diseased conditions. This finding is in contrast to previous reports showing a 
95% N-glycosylation site occupancy for hemoglobin-affinity enriched haptoglobin38. It is conceivable, that the 
affinity enrichment introduces a bias towards glycosylated haptoglobin. Whether haptoglobin binding to free 
Figure 3. N-glycosylation site occupancy in CDG and NAFLD. The site occupancy in % of the transferrin 
(a), haptoglobin (b), IgA1 (c) and IgG2 (d) glycopeptides is plotted for the CDG, NAFLD and healthy control 
samples. Each data point represents the mean value of triplicate measurements starting with the sample 
preparation. The biological mean values with error bars (SEM) are indicated in each group of serum samples 
plotted. Differences between groups were calculated using the Mann-Whitney statistical test. Differences were 
considered significant with p < 0.05 (*). ns = non-significant. The CDG samples were obtained from PMM2-
CDG, ALG11-CDG, ALG1-CDG, ALG6-CDG, MPDU1-CDG and RFT1-CDG patients, and grouped into 
severe, moderate and mild phenotypes. The NAFLD group is divided into liver steatosis and NASH samples.
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hemoglobin in vivo is affected by the glycosylation status of the carrier protein is not clear. The physiological 
significance of haptoglobin N-glycosylation site occupancies remain to be demonstrated. Nevertheless, hapto-
globin appears to be more adequate for detecting changes in glycosylation frequency than other serum proteins 
examined to date. Haptoglobin glycosylation has been investigated in previous studies, comparing hepatocellu-
lar carcinoma patients originated from ALD, hepatitis C and hepatitis B virus infection. Quantitative analysis 
of purified haptoglobin N-glycans indicated an increase in bi-fucosylated glycans in hepatocellular carcinoma 
patients, providing a potential use as a marker for the detection of early stage hepatocellular carcinoma patients39. 
In these studies however, the glycosylation site occupancy has not been addressed. A comprehensive assessment 
of the haptoglobin glycosylation status from differing liver disease conditions might be valuable for identifying 
predictive liver disease markers in future studies.
ID Sample
Clinical 
score Age Gender Steatosis level
Hepatocyte  
ballooning Inflammation Fibrose stage
Differential 
diagnosis
012 Steatosis < 3 53 f mixed vesicular isolated ballooning borderline to steatohepatitis Fibrose stage 2
013 Steatosis < 3 40 m mixed vesicular no ballooning some portal inflammation none
015 Steatosis < 3 34 m mixed vesicular no ballooning reported none focal pericellular fibrosis
016 Steatosis < 3 40 f mainly micovesicular no ballooning none minor pericellular fibrosis
nutritional 
or medicinal 
intoxication
014 NASH 5 40 m mixed vesicular ballooning minor lobular inflammation
isolated minor 
pericellular fibrosis
017 NASH 3 52 m moderate mixed vesicular isolated ballooning no lobular or portal inflammation
no portal or pericellular 
fibrosis
018 NASH 4 50 f moderate mainly macrovesicular discreet ballooning
sparse mixed cellular 
inflammarory portal 
infiltration
discreet pericentral 
fibrosis and 
perisinusoidal collagen 
deposition
019 NASH 5–6 54 f mainly macrovesicular ballooning
isolated, sparse 
portal inflammatory 
infiltration
discreet focal pericellular 
fibrosis
020 NASH 4 54 f mixed vesicular pronounced ballooning focal necro-inflammatory activity
perisinusoidal, portal 
and periportal fibrosis, 
focal septum formation
021 NASH 4 31 m mixed vesicular isolated ballooning no lobular or portal inflammation
minor pericellular 
fibrosis
022 NASH 6 58 m mixed vesicular ballooning portal and lobular inflammation septal and portal fibrosis
additional viral 
hepatitis appears 
to be possible
023 NASH * 66 f mainly macrovesicular ballooning no definite florid lobular inflammation
minor focal pericellular 
fibrosis
Table 3.  NAFLD clinical data. ID = unique sample identifier, the clinical score values are displayed as NAFLD 
activity scores31.
Figure 4. Western-blot analyses of haptoglobin from CDG and NAFLD samples. Lanes with ID 002-005 
show CDG samples with increasing severity of the clinical symptoms; ID 002, PMM2-CDG, mild, ID 004, 
PMM2-CDG, moderate, ID 005, PMM2-CDG, severe30. ID 034 shows the ALG11-CDG sample and lanes with 
ID 013-022 show NAFLD samples with increasing clinical scores; ID 013, steatosis, score < 3, ID 018, NASH, 
score 4, ID 022, NASH, score 631. The arrow indicates the migration position of fully glycosylated haptoglobin. 
The migration positions of the protein molecular weight markers are indicated at the left in kDa. The percent 
site occupancy of the corresponding haptoglobin glycopeptide is indicated below the lanes (% SO = percent site 
occupancy, ID = unique sample identifier, HC = pooled healthy control serum).
www.nature.com/scientificreports/
9Scientific RepoRts | 6:33927 | DOI: 10.1038/srep33927
The N-glycosylation site occupancy of serum proteins has not been determined in NAFLD patients in pre-
vious studies. Originally, reduced glycosylation was observed in ALD and the determination of CDT levels are 
used as a reliable means to monitor disease progression and patient compliance28. The cytochrome CytP2E1 is 
upregulated in ALD and NASH, and made responsible for the increased production of reactive oxygen species 
in the corresponding tissue40. In this regard it is surprising to find opposing glycosylation levels in NAFLD and 
ALD patients, indicating that the regulation of N-glycosylation site occupancy is independent of CytP2E1 medi-
ated oxidative stress. In search for diagnostic markers to differentiate alcoholic hepatitis from NASH, Ohtsuka 
et al.8 found increasing levels of CDT in alcoholic hepatitis patients in comparison to patients with NASH. The 
relationship of patient to healthy control samples, however has not been investigated, leaving questions about 
the levels of CDT in NASH unanswered. Alterations in the N-glycosylation site occupancy are a result of inter-
ferences in the biosynthesis upstream to the transfer of glycan precursors to the newly synthesized polypeptide 
in the ER, whereas alterations in the N-glycans structures can be attributed to interferences in the glycan matu-
ration and processing in the Golgi. Deficient glycan processing enzymes or defective Golgi associated proteins 
can be involved in this instance. Here we determined a clear hyperglycosylation of the haptoglobin peptide in 
sera obtained from liver steatosis patients. The hyperglycosylation of haptoglobin occurred independent of liver 
inflammation, prior to the development of NASH in the early staged NAFLD patients. The observed occurrence 
of hyperglycosylation in NAFLD might be a result of interferences early in the biosynthesis of the N-glycans. On 
the other hand, increases in site occupancy will most likely affect the N-glycan maturation, due to an increased 
load of substrate for the Golgi localized glycan processing enzymes. For instance, the undergalactosylation of 
serum N-glycans was proposed as a glycomarker for liver inflammation and NASH-related fibrosis11,12. In sub-
sequent studies, increased fucosylation of haptoglobin N-glycans as a diagnostic marker for NASH were sug-
gested41,42. In this context, analyzing the glycosylation site occupancy provides a sensitive and specific means to 
diagnose liver steatosis early in NAFLD before the development of NASH.
In conclusion our data suggest that under physiological conditions N-glycosylation sites can be occupied 
with different frequencies, depending on the glycoprotein, an instance as yet not described in serum proteins. 
For the glycoproteins investigated, glycosylation site occupancies were also dependent on the tissue of origin. 
Furthermore, no changes to healthy controls were observed with the immunoglobulin derived peptides in the 
CDG patients. Our third finding that in NAFLD haptoglobin is hyperglycosylated opens new opportunities in 
biomarker research for fatty liver diseases.
Methods
Serum Samples. Ten CDG samples obtained from patients with confirmed diagnosis of PMM2-CDG, 
Alg11CDG, Alg1-CDG, Alg6-CDG, MPDU1-CDG and RFT1-CDG and 5 healthy control samples were used. 
Twelve NAFLD samples, 4 with confirmed diagnosis of steatosis and 8 samples with confirmed diagnosis of 
NASH were evaluated. The study protocol was approved by the Ethics Committee of the University Hospital 
Zurich and all NAFLD patients were provided with written, informed consent. All experiments were performed 
in accordance with the guidelines and regulations of the Ethics Committee of the University Hospital Zurich.
Preparation of serum samples. One μ l of serum was diluted 20-fold to give 20 μ l of 50 mM triethylam-
monium bicarbonate buffer (Sigma, Switzerland), pH 8.5, 0.1% (w/v) SDS, 5 mM tris(2-carboxyethyl)phosphine 
(ThermoFischer, USA) and incubated for one hour at 60 °C. The samples were cooled to room temperature, 10 μl 
of freshly prepared 50 mM iodoacetamide were added and the samples were incubated at room temperature in 
the dark. After 40 min, a five-fold excess of dithiothreitol over iodoacetamide was added to quench the reaction 
and the samples were digested with trypsin for 16 h at 37 °C (10 μ l of 0.5 μ g trypsin/μ l in H2O, sequencing grade, 
Roche, Switzerland). The samples were acidified with 4 μ l of 10% (v/v) acetic acid and stored at − 20 °C until 
further processing. A 0.5 ml Dowex AG50 × 8 column was pre-cycled with 5% (v/v) ammonia in 25% (v/v) ace-
tonitrile and equilibrated with 0.8% (v/v) acetic acid in 25% (v/v) acetonitrile. The samples were diluted to 8 ml 
with 0.8% (v/v) acetic acid, 25% (v/v) acetonitrile, loaded onto the column, washed with 6 ml of 0.8% (v/v) acetic 
acid, 25% (v/v) acetonitrile and eluted with 2 ml 5% (v/v) ammonia, 25% (v/v) acetonitrile. The volumes of the 
eluates were concentrated by rotary evaporation before lyophilization. The dried samples were re-dissolved in 
44 μ l 20 mM ammonium bicarbonate buffer prepared with 18O-H2O (> 97% 18O, Cambridge Isotope Laboratories, 
USA) and 6 units of N-glycosidase F (Roche, Switzerland) in 20 mM 18O-H2O ammonium bicarbonate buffer 
were added. The peptides were de-glycosylated for 6 h at 37 °C and aliquots were desalted with ZipTip C18 tips 
(Millipore, USA) prior submission to mass spectrometry.
A standard peptide mix consisting of synthetic peptides with c-terminal labeled arginine or lysine corre-
sponding to the target glycopeptide sequences with asparagine or aspartic acid at the glycosylation sites was 
prepared (> 70% purity, Intavis AG, Germany, Table 1, Supplemental Fig. 3). The peptides were dissolved in 2% 
(v/v) acetonitrile, 0.1% (v/v) formic acid at a concentration of 100 or 50 fmol per μ l for the transferrin, IgG2 and 
IgA1 peptides and 10 or 5 fmol per μ l for the haptoglobin peptides. An aliquot corresponding to 4% of the sample 
was desalted with ZipTip C18 tips, dried by rotary evaporation, and re-dissolved in 10 μ l of the standard peptide 
mix. For each sample, 4 μ l were injected onto a nano-frit column (15 cm × 75 μ m; OD 375 μ m; beads, Magic C18 
AQ, 3 μ m, 200 Å; Bischoff Chromatography, Germany), connected to a spray tip (PicoTip emitter, New Objective, 
USA), coupled to an Eksigent nano LC system (Eksigent, AB Sciex, USA). The column was kept at 50 °C. Peptides 
were eluted using a gradient from 3 to 45% acetonitrile, 0.1% (v/v) formic acid in water for 40 min, and a flow rate 
of 300 nl/min.
LC-MS-MS peptide sequencing. Glycosylation site containing peptides were identified by LC-MS-MS 
peptide sequencing. The dried peptides were re-suspended in 3% (v/v) acetonitrile and 0.1% (v/v) formic acid and 
analyzed on a LTQ-Orbitrap Velos mass spectrometer (ThermoFischer Scientific, USA) coupled to an Eksigent 
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nano LC system (Eksigent, AB Sciex, USA). The analyses were performed in the data-dependent acquisition mode. 
The ten most intense precursor ions in the mass range m/z 300–2000 were selected for HCD spectrum acquisition 
with a normalized collision energy of 40 V. Single charged precursors and unassigned charge states were rejected 
and the minimal signal intensity required for MS2 was 2000 counts. Dynamic exclusion was switched on with 
an exclusion list size of 50, and an exclusion mass width relative to mass of ± 10 ppm. Values were excluded from 
MS/MS for 45 s. The instrument was calibrated externally according to the manufacturer’s instructions. From the 
LC-MS-MS peptide sequencing results of a healthy control serum, treated with PNGase F in 18O-H2O buffer, a 
spectral library was generated and imported into Skyline for the MRM-method development. The glycopeptides 
were selected on the basis of robust detection after identification using the Mascot search engine (Matrix Science, 
UK; Version: 2.4.1.). Mascot was set up to search the human protein entries of the Swissprot database (down-
loaded 04.12.2012, 170103 entries, containing decoy dataset and common contaminants) assuming the digestion 
enzyme trypsin with maximal one missed cleavage. Mascot was searched with a fragment ion mass tolerance of 
0.60 Da and a parent ion tolerance of 10.0 ppm. Carbamidomethyl-alkylation of cysteine was specified as fixed 
modifications. Oxidation of Met, Gln conversion to pyro-Glu and 18O-incorporation in Asn residues were speci-
fied in Mascot as variable modifications. Suitable tryptic peptides were selected on the basis of high peptide iden-
tification scores for the synthesis of isotopically labeled standards. Selected peptides should not contain missed 
cleavage sites or methionine whenever possible. The peptide length was kept short with maximal one missed 
tryptic cleavage site to enable reproducible and unambiguous identifications and chromatographic separation of 
deaminated and non-deaminated peptide variants.
MRM-method development. Four glycosylation site containing peptides were selected from four pro-
teins, based on robust detection in LC-MS-MS peptide sequencing. Theoretical MRM transitions were computed 
using the Skyline software environment, and six transition per precursor were analyzed43. LC-MRM-MS files 
were imported and precursor-fragment transitions were manually inspected for correct assignment and accu-
rate peak integration. Precursor peaks were identified by co-elution of transitions derived from the isotopically 
labeled standard peptides included in the samples. The four transitions showing most intense signals and highest 
selectivity for each precursor in comparison to the spectral library were selected. Whenever possible, transitions 
including the glycosylation site in the fragment ion were selected. For the four selected peptides a list was assem-
bled of 104 transitions (Supplemental Table 1). The isotopically labeled standard peptide mix was used to validate 
the transitions and to empirically optimize collisional energies (Table 1).
The analyses were performed in positive ion mode on a QTRAP 5500 mass spectrometer (AB Sciex, USA) 
equipped with a nanospray ion source. The interface temperature was set to 170 °C, an ion spray voltage from 
2000–2500 V, the ion source gas pressure was 6–10 psi, the curtain gas pressure was 25 psi, and the collision gas 
set to medium was used. The declustering potential had a value of 80 V, collision cell exit potential of 13 V, and 
entrance potential of 10 V. Further settings were unit resolution for both Q1 and Q3 and 3 ms pause between mass 
ranges. The total scan time was 2.6 s.
For quantitative calculations of peptide abundances only transitions unique to the target peptide were used 
(Table 1). The product peak areas were validated manually and assessed for the co-elution of the sample peptides 
with the isotope labeled standard peptides added to the samples. Molar relative response factors (MRRF) were 
computed for spontaneously deaminated peptides (i.e. deamination-16O, not glycosylated, MRRF-16O), enzymat-
ically deaminated peptides (i.e. deamination-18O, deglycosylated, MRRF-18O) and non-deaminated peptides (i.e. 
not glycosylated, MRRF-N):
=MRRF
area
area
sample
standard
The relative glycosylation site occupancy was calculated using the MRRF:
=
−
− + − + −
∗glycosylated peptide MRRF O
MRRF O MRRF O MRRF N
%
( )
100
18
16 18
The portion of spontaneously deaminated peptides was calculates as follows.
=
−
− + − + −
∗glycosylated peptide MRRF O
MRRF O MRRF O MRRF N
%
( )
100
16
16 18
Western blot analysis of serum haptoglobin. Serum samples were diluted 1:250 in H2O and serum 
protein precipitated by the addition of 1/10 volume 100% (w/v) trichloroacetic acid (w/vol). Precipitated protein 
was centrifuged, protein pellets washed with ice-cold acetone and dried at 95 °C for 10 min. For SDS-PAGE, dried 
pellets were dissolved in 200 μ l 2x Laemmli Sample Buffer containing 5% (v/v) 2-mercaptoethanol and boiled 
for 5 min at 95 °C. Proteins were separated on a 10% (w/v) SDS polyacrylamide gel and blotted onto Protran 
BA85 nitrocellulose membrane (Whatman) and blocked at room temperature for 1 h in PBS-0.1% (v/v) Tween 
− 5% (w/v) non-fat dry milk (PBSTP). The membrane was incubated for 1 h at room temperature with 1/3500 
rabbit-α -human haptoglobin (DakoCytomation), followed by incubation with 1/5000 goat-α -rabbit –HRPO 
(Santa Cruz). All incubation steps were performed in PBSTP and the membrane was subsequently washed three 
times in PBS − 0.1% Tween. Detection occurred using ECL (GE Healthcare Life Sciences).
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